Article

Case Report: Shortness of Breath After Cefalexin

Our latest case report from Brady Pregerson, MD, features a 62 y/o male with a history of obesity, CAD, anxiety, and COPD presenting with SOB after stating cefalexin. Can you determine the correct diagnosis?

History: A 62-year-old male with a history of obesity, coronary disease, anxiety, and COPD presents to the emergency department for 2 days of intermittent shortness of breath after starting Keflex for cellulitis. He denies any chest pain, fever, rash, throat or lip swelling, or cough. He states the SOB seems to get worse about an hour after taking Keflex but then gradually gets better, which is why he thinks it may be an allergic reaction. His inhalers don’t seem to help.

Exam: Vital signs are normal including pulse ox and respiratory rate. Exam is otherwise normal except for the cellulitis which is both in his groin below his pannus and in his right lower leg. Specifically, there is no rash, oral swelling, rales, or wheezing.

An EKG is performed:

EKG reading

COMPUTER EKG READ: Sinus rhythm with occasional PVC. Possible inferior infarct, age undetermined


Based on this EKG, what diagnosis should you suspect?

A) Anxiety

B) Allergic reaction

C) Pulmonary Embolism

D) Acute Coronary Syndrome

E) COPD exacerbation


Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.